Mevion Medical Systems has received a medical device license from Health Canada for its Mevion S250i proton therapy system with the company's Hyperscan pencil beam scanning (PBS) technology.
The nod enables Mevion to begin selling the system in Canada. Mevision says the system's Hyperscan technology maximizes the benefits of proton therapy by using an adaptive multileaf collimator to sharpen the radiation beam, enabling delivery of a more precise and conformal radiation dose to patients.
Mevion S250i received U.S. Food and Drug Administration clearance and the CE Mark for Europe in 2017.
